Heterozygous Familial Hypercholesterolemia

Metabolic·MeSH: Hyperlipoproteinemia Type II

Prevalence

0.5 / 100K

8 drugs in development·6 companies·6 clinical trials

Drug Pipeline by Phase

Compare drugs

colesevelam vs pitavastatincolesevelam vs Enlicitide Decanoatecolesevelam vs mgl-3196

Frequently asked questions

How many drugs are in development for Heterozygous Familial Hypercholesterolemia?

BioSniper tracks 8 drugs in development for Heterozygous Familial Hypercholesterolemia across 6 companies.

How many clinical trials target Heterozygous Familial Hypercholesterolemia?

There are 6 clinical trials targeting Heterozygous Familial Hypercholesterolemia tracked by BioSniper.

What is the prevalence of Heterozygous Familial Hypercholesterolemia?

The estimated prevalence of Heterozygous Familial Hypercholesterolemia is approximately 0.5 per 100,000 population.

Deep-dive into Heterozygous Familial Hypercholesterolemia

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    Heterozygous Familial Hypercholesterolemia — Drugs in Development & Clinical Trials | BioSniper